Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIBR 1048 Polymorph II vs Polymorph I in Healthy Subjects
NCT02170974Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2004
- Primary completion
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration-time curve from 0 to infinity at 72 hours, Area under the plasma concentration-time curve from 0 to the last quantifiable data point at 72 hours and 1 more. Started Jul 2004; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02170974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170974.